絞り込み

16535

広告

Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer.

著者 Kaneda T , Yoshioka H , Tamiya M , Tamiya A , Hata A , Okada A , Niwa T , Shiroyama T , Kanazu M , Ishida T , Katakami N
BMC Cancer.2018 Jan 02 ; 18(1):6.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (55view , 0users)

Full Text Sources

Miscellaneous

LUX-Lung 3 showed afatinib improved progression-free survival (PFS) compared with cisplatin plus pemetrexed in patients with epidermal growth factor receptor (EGFR) mutations. In this study, chemotherapy efficacy tended to differ between patients with Leu858Arg (L858R) point mutation and Exon 19 deletion (Del-19); PFS in L858R patients (8.1 months) was greater than in Del-19 patients (5.6 months). We investigated whether there is any difference in efficacy of cisplatin plus pemetrexed between Del-19 and L858R.
PMID: 29291705 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード